A Phase 2 interventional study of Ianalumab in Primary Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia, sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions.
Argentina, Belgium, China, Czechia, France, Germany, Hungary, Italy, Malaysia, Romania, Singapore, Spain, Turkey (Türkiye), United Kingdom
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 2, and was the 11th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals
Ages 5–17
By country, each count listing its studies:
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2026.
Median enrollment 39 across the 12 interventional studies, 150 across the 3 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Purpura, Thrombocytopenic, Idiopathic by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07786077Novartis PharmaceuticalsA Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is intended to explore the efficacy and safety of a second course of ianalumab after experiencing treatment failure in the pivotal Primary Immune Thrombocytopenia (ITP) trials (CVAY736I12301, CVAY736Q12301) and after loss of durable response in the pivotal Warm Autoimmune Hemolytic Anemia (wAIHA) trial (CVAY736O12301).
This is a multicenter, Phase 2 exploratory study to assess the efficacy and safety of a second course of ianalumab in adults with ITP and wAIHA who have previously benefited from ianalumab.
All participants will receive ianalumab at the dose of study treatment from which they previously derived benefit.
After completion of the screening period, participants who do not meet treatment failure criteria during treatment period will enter the safety and efficacy follow-up, whereas participants who reported a treatment failure during the treatment period will enter the safety follow-up only.
The study will end once all participants have completed safety and/or efficacy follow-up since their last dose of ianalumab or discontinued the study earlier.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Primary ITP patients:
For Primary or Secondary wAIHA patients:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ianalumab lower dose
Biological: Ianalumab
Participants will receive ianalumab higher dose
Biological: Ianalumab
Concentrate for solution for infusion for intravenous use
Also known as: VAY736
Treatment failure free (yes, no) for participants with Immune Thrombocytopenia (ITP)
Treatment failure free (yes, no) by 12 months after start of second course of ianalumab at assigned dose.
Time frame: From treatment start date until the events indicative of treatment failure (up to 2 years after last dose)
Durable response for participants with Warm Autoimmune Hemolytic Anemia (wAIHA)
Durable response (hemoglobin (Hb) ≥10 g/dL and ≥2 g/dL increase from baseline) for a period of at least 8 consecutive weeks, between W9 and W25 in the absence of rescue or prohibited treatment prior to that durable response achievement.
Time frame: At least 8 consecutive weeks, between week 9 and week 25
Response rate in participants with ITP only
Percentage of participants with ITP achieving a response among all participants who received a second course of ianalumab, and among cohorts and/or group of cohorts.
Time frame: from treatment start to end of study (up to 2 years after last dose)
Complete response rate in participants with ITP only
Percentage of participants with ITP achieving a complete response among all participants who received a second course of ianalumab, and among cohorts and/or group of cohorts.
Time frame: from treatment start to end of study (up to 2 years after last dose)
Number and percentage of participants receiving new ITP therapy only
Number and percentage of participants who need new ITP therapy among all the participants who received a second course of ianalumab, and among cohorts and/or group of cohorts.
Time frame: from treatment start to end of study (up to 2 years after last dose)
Response and complete response in participants with wAIHA only
Percentage of participants with wAIHA achieving a response and complete response among all participants who received a second course of ianalumab and among cohorts and/or group of cohorts.
Time frame: from treatment start to end of study (up to 2 years after last dose)
Number and percentage of participants receiving new wAIHA therapy only
Number and percentage of participants who need new wAIHA therapy among all the participants who received a second course of ianalumab, and among cohorts and/or group of cohorts.
Time frame: from treatment start to end of study (up to 2 years after last dose)
Number and percentage of participants receiving rescue treatment
Number and percentage of participants who need rescue treatment among all the participants who received a second course of ianalumab, and among cohorts and/or group of cohorts.
Time frame: from treatment start to end of study (up to 2 years after last dose)
Number of severe infections and percentage of participants with severe infection
This is to assess the safety profile of ianalumab.
Time frame: from treatment start to end of study (up to 2 years after last dose)
Ianalumab concentration in serum
Assess the pharmacokinetics of a second course of ianalumab treatment.
Time frame: after first dose (pre dose 0 and 672 hours) and at study end (up to 2 years after last dose of Ianalumab)
Incidence of anti-ianalumab antibodies in serum (ADA assay) over time
Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of Ianalumab.
Time frame: up to end of treatment (Week 16), end of study (up to 2 years after last dose of Ianalumab)
Titer of anti-ianalumab antibodies in serum (ADA assay) over time
Assess the immunogenicity of second course of ianalumab treatment.
Time frame: up to end of treatment (Week 16), end of study (up to 2 years after last dose of Ianalumab)
No study locations are listed for this record.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Aug 2030, 50 months later.
How these figures are worked out, and which studies are left out of them.
The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions.
Argentina, Belgium, China, Czechia, France, Germany, Hungary, Italy, Malaysia, Romania, Singapore, Spain, Turkey (Türkiye), United Kingdom
The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions.
Argentina, Belgium, China, Czechia, France, Germany, Hungary, Italy, Malaysia, Romania, Singapore, Spain, Turkey (Türkiye), United Kingdom
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ianalumab
Purpura, Thrombocytopenic, Idiopathic →